Press Releases April 15, 2026 08:00 PM

Trupanion Announces First Quarter 2026 Earnings Release and Conference Call

Trupanion schedules Q1 2026 earnings release and conference call to discuss financial results and guidance

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
TRUP

Trupanion, a leader in pet medical insurance, announced that it will release its financial results for the first quarter of 2026 on April 30, followed by a conference call and webcast to discuss its performance, guidance, and management insights. The company insures over one million pets across North America and parts of Europe, utilizing patented technology to pay veterinarians directly.

Trupanion Announces First Quarter 2026 Earnings Release and Conference Call
TRUP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Trupanion will report its Q1 2026 financial results after market close on April 30, 2026, with an associated conference call and webcast.
  • The company currently insures over one million cats and dogs in the US, Canada, and parts of Europe.
  • Trupanion's technology enables direct payments to veterinarians at checkout, differentiating its service offering.

SEATTLE, April 16, 2026 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, announced today it will report financial results for its 2026 first quarter after the market closes on Thursday, April 30, 2026. The company will host a conference call that day beginning shortly after 1:30 p.m. PT / 4:30 p.m. ET.

A live webcast discussing results, guidance and management observations will be available on Trupanion's Investor Relations site under Investor Events at http://investors.trupanion.com and will be archived online for 3 months upon completion of the conference call. A slide presentation will also be available on the site.

Participants can access the conference call by dialing 1-844-676-1342 (United States) or 1-412-634-6683 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10207244.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,000,000 pets currently enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts on eligible expenses for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company or ZPIC Insurance Company and, in Canada, by its wholly-owned insurance entity GPIC Insurance Company or by Accelerant Insurance Company of Canada. For more information, please visit trupanion.com.

Contacts 

Laura Bainbridge, Senior Vice President, Corporate Communications
Gil Melchior, Director, Investor Relations
[email protected]


Risks

  • Financial results may not meet market expectations, impacting investor sentiment in the pet insurance and broader insurance sectors.
  • Economic downturns could reduce consumer discretionary spending on pet insurance, affecting revenue growth.
  • Regulatory changes in insurance practices across North America and Europe could impact operational costs and compliance requirements.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026